Latest News & Features
Americas
Patent Trial and Appeal Board rules all challenged claims were unpatentable | Decision follows Federal Circuit review that revived Apple’s challenge. 18 February 2025
Careers
David Por joins the firm’s Paris team as partner | New hire brings two decades of experience, including in healthcare and life sciences. 18 February 2025
Americas
The former USPTO director has filed her first amicus brief since rejoining private practice, arguing that instructions issued in a Texas court are “legally incorrect”. She tells Sarah Speight why this matters. 18 February 2025
Unified Patent Court
Court of Appeal says in-house representatives can appear before the court | Patent attorneys with ‘administrative and financial powers’ or shares remain barred | Decision specific to Microsoft v Suinno Mobile & AI Technologies Licensing. 13 February 2025
Americas
Nominations open as D&I values face growing backlash on both sides of the pond | Research shows equality efforts result in creativity and productivity | Categories include Influential Women in IP, Diversity Champions, and Future Champions. 13 February 2025
Americas
The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity. 13 February 2025
Americas
Key ruling in favour of Kansas-based biotech on genetically engineered proteins from China | Court supports ITC position | Small market segments can be substantial enough for domestic industry requirement. 11 February 2025
Careers
The firm created a role for Naoise Gaffney, whose unusual background and high profile in Ireland brings a ‘different perspective’, finds Sarah Speight. 11 February 2025
Careers
Five partners from Knobbe Martens join the firm | New arrivals bolster Morgan Lewis’s capabilities in patent and trademark litigation. 11 February 2025
Americas
Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen. 6 February 2025